

# Luca Pani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2047060/publications.pdf>

Version: 2024-02-01

180  
papers

6,180  
citations

70961

41  
h-index

82410

72  
g-index

187  
all docs

187  
docs citations

187  
times ranked

8784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study. <i>Pain Medicine</i> , 2022, 23, 396-402.	0.9	5
2	Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. <i>Neurological Sciences</i> , 2022, 43, 3823-3830.	0.9	11
3	Occlusal splint therapy in patients with MÃ©niÃ©re's disease and temporomandibular joint disorder. <i>Acta Otorhinolaryngologica Italica</i> , 2022, , 1-8.	0.7	1
4	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	4.1	68
5	Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. <i>CNS Spectrums</i> , 2022, 27, 236-236.	0.7	0
6	A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire. <i>CNS Spectrums</i> , 2022, 27, 235-235.	0.7	3
7	Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. <i>Neurological Sciences</i> , 2021, 42, 4193-4202.	0.9	20
8	Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic. <i>Frontiers in Neurology</i> , 2021, 12, 647995.	1.1	5
9	New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. <i>Clinical Drug Investigation</i> , 2021, 41, 529-537.	1.1	1
10	Digital Phenotyping and Dynamic Monitoring of Adolescents Treated for Cancer to Guide Intervention: Embracing a New Era. <i>Frontiers in Oncology</i> , 2021, 11, 673581.	1.3	13
11	Predictors of response to erenumab after 12 months of treatment. <i>Brain and Behavior</i> , 2021, 11, e2260.	1.0	34
12	Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 181-185.	0.9	1
13	A case-control study of visually evoked postural responses in childhood with primary headaches. <i>Neurological Sciences</i> , 2020, 41, 305-311.	0.9	4
14	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. <i>Journal of Translational Medicine</i> , 2020, 18, 162.	1.8	42
15	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	2.0	121
16	Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. <i>Schizophrenia Research: Cognition</i> , 2019, 18, 100155.	0.7	3
17	Nutraceuticals: opening the debate for a regulatory framework. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 659-672.	1.1	246
18	The Italian compassionate use of sofosbuvir in <sc>HCV</sc> patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 738-763.	1.1	3
20	Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 900-902.	1.1	0
21	Safety of Antiplatelet Agents: Analysis of "Real-World" Data from the Italian National Pharmacovigilance Network. <i>Clinical Drug Investigation</i> , 2017, 37, 1067-1081.	1.1	7
22	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
23	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	0.8	3
24	Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 253.	0.7	6
25	Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases. <i>International Journal of Cardiology</i> , 2016, 224, 406-411.	0.8	14
26	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.	3.1	9
27	Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 730-742.	2.3	20
28	Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 168-172.	1.2	32
29	Identification and validation of biomarkers for autism spectrum disorders. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 70-70.	21.5	117
30	Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. <i>International Journal of Cardiology</i> , 2016, 203, 217-220.	0.8	36
31	Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1712-1718.	1.1	10
32	Association of neovascular age-related macular degeneration with month and season of birth in Italy. <i>Aging</i> , 2016, 9, 133-141.	1.4	3
33	MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 210-213.	0.2	44
34	Transparency in medical research: Time for a paradigm shift. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 2-3, 1-3.	1.0	0
35	Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. <i>Pharmacological Research</i> , 2015, 102, 12-21.	3.1	9
36	Generic and biosimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA). <i>Journal of Generic Medicines</i> , 2015, 12, 79-80.	0.0	1

#	ARTICLE	IF	CITATIONS
37	The future is now: Model-based clinical trial design for Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 210-214.	2.3	68
38	Alternative Pricing Strategies for Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 857.	3.8	10
39	An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. <i>BioDrugs</i> , 2015, 29, 285-300.	2.2	30
40	Daptomycin in paediatrics: current knowledge and the need for future research. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 643-648.	1.3	22
41	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015, 36, 2454-2462.	1.0	94
42	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	2.9	11
43	Transparency in medical research: Time for a paradigm shift. <i>International Journal of Cardiology</i> , 2015, 186, 259-260.	0.8	4
44	Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 903-911.	0.9	6
45	The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 221-222.	21.5	13
46	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015, 385, 750-752.	6.3	46
47	Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3838-3839.	0.8	9
48	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance. <i>Drug Safety</i> , 2015, 38, 1211-1218.	1.4	12
49	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.	0.8	88
50	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.4	9
51	Towards a framework for treatment effectiveness in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1867.	1.0	18
52	High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 430-437.	1.7	86
53	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1346-1353.	1.1	39
54	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. <i>Journal of Internal Medicine</i> , 2014, 275, 251-283.	2.7	540

#	ARTICLE	IF	CITATIONS
55	Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. Paediatric Anaesthesia, 2014, 24, 625-631.	0.6	9
56	Are we ready? What is missing and what is needed? A regulator's perspective. Orphanet Journal of Rare Diseases, 2014, 9, O25.	1.2	0
57	Managed entry agreements. Orphanet Journal of Rare Diseases, 2014, 9, O27.	1.2	2
58	Insights Into the Decision Making of Advisory Groups to the Italian Medicines Agency. Therapeutic Innovation and Regulatory Science, 2014, 48, 696-701.	0.8	4
59	Licensing of Generic Medicines, are there Any Challenges Left? A Pharmaceutical Regulatory Perspective. Scientia Pharmaceutica, 2014, 82, 847-856.	0.7	3
60	Reflections on Decisions Taken on Well Established Use Medicinal Products by EU Regulators and the ECJ: A Pharmaceutical Regulatory Perspective. Scientia Pharmaceutica, 2014, 82, 655-663.	0.7	10
61	Validated Method to Determine Quetiapine and Norquetiapine in Microsomal Matrix by LC MS-MS: Implication in Quetiapine Metabolism. Chromatographia, 2014, 77, 75-82.	0.7	5
62	Stamina therapies: Let the record stand. Nature, 2014, 506, 434-434.	13.7	4
63	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421.	0.4	77
64	The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs, 2014, 28, 421-53.	2.7	238
65	THE USE OF PLACEBO IN RANDOMIZED CONTROLLED TRIALS IN SCHIZOPHRENIA: A REGULATOR'S VIEW. Schizophrenia Research, 2014, 153, S14.	1.1	0
66	Steps forward in regulatory pathways for acute and chronic heart failure. ESC Heart Failure, 2014, 1, 87-93.	1.4	4
67	The Italian Medicines Agency Experience With Hta Scientific Advice Activities: A Comprehensive Analysis Of Three Years Of National And International Activities. Value in Health, 2014, 17, A27-A28.	0.1	1
68	Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study. PLoS ONE, 2014, 9, e98101.	1.1	25
69	A focus on real life data concerning antidiabetic drugs: The experience of aifa monitoring registry. Value in Health, 2013, 16, A174.	0.1	0
70	Regulatory evaluation of Glybera in Europe - two committees, one mission. Nature Reviews Drug Discovery, 2013, 12, 719-719.	21.5	54
71	Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opinion on Biological Therapy, 2013, 13, 1343-1346.	1.4	10
72	Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. British Journal of Clinical Pharmacology, 2013, 75, 1149-1151.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Is HCMV Vaccine an Unmet Need? The State of Art of Vaccine Development. International Journal of Immunopathology and Pharmacology, 2013, 26, 15-26.	1.0	4
74	Analysis of <i>CYP2D6</i> Allele Frequencies and Identification of Novel SNPs and Sequence Variations in Sardinians. ISRN Genetics, 2013, 2013, 1-10.	0.1	5
75	Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. ISRN Genetics, 2013, 2013, 1-10.	0.1	1
76	DSM-5 and clinical trials in psychiatry: challenges to come?. Nature Reviews Drug Discovery, 2012, 11, 583-584.	21.5	7
77	Discriminative Hypomania Checklist-32 Factors in Unipolar and Bipolar Major Depressive Patients. Psychopathology, 2012, 45, 390-398.	1.1	18
78	The Italian post-marketing registries. Pharmaceutical Programming, 2012, 5, 57-60.	0.1	15
79	European licensing of maintenance treatment in schizophrenia. Lancet, The, 2012, 380, 562-563.	6.3	1
80	The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma. European Neuropsychopharmacology, 2012, 22, 804-811.	0.3	10
81	PIN57 Public Expenditure for Antiretroviral Treatment and Projected Cost-Savings After the Entry of Generic Antiretrovirals in the Italian Pharmaceutical Market. Value in Health, 2012, 15, A247.	0.1	0
82	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Medicinal Chemistry Journal, 2012, 6, 1-14.	0.9	12
83	NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behavioural Brain Research, 2012, 234, 192-204.	1.2	31
84	PHP39 The "Weight" of Orphan Drugs in the European Pharmaceutical Policy. A Focus on the Expenditure and the Utilization of Orphan Drugs in Five European Union Countries. Value in Health, 2012, 15, A20.	0.1	1
85	PHP99 How to Deal With Decision Uncertainty? The Italian Experience With Managed Entry Agreements. Value in Health, 2012, 15, A31.	0.1	1
86	Subthreshold depression in older subjects: An unmet therapeutic need. Journal of Nutrition, Health and Aging, 2012, 16, 909-913.	1.5	17
87	Unexplained Somatic Symptoms during Major Depression: Prevalence and Clinical Impact in a National Sample of Italian Psychiatric Outpatients. Psychopathology, 2011, 44, 116-124.	1.1	25
88	Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behavioural Brain Research, 2011, 217, 432-438.	1.2	33
89	Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden " Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. European Neuropsychopharmacology, 2011, 21, 781-788.	0.3	49
90	Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. Neuropsychiatric Disease and Treatment, 2011, 7, 217.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Are "social drugs" (tobacco, coffee and chocolate) related to the bipolar spectrum?. Journal of Affective Disorders, 2011, 133, 227-233.	2.0	17
92	Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials. Human Psychopharmacology, 2011, 26, 307-312.	0.7	4
93	Oct4 expression in <i>in vitro</i> -produced sheep blastocysts and embryonic stem-like cells. Cell Biology International, 2010, 34, 53-60.	1.4	22
94	Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. Behavioural Pharmacology, 2010, 21, 649-653.	0.8	11
95	Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. Pharmacogenomics, 2010, 11, 559-571.	0.6	12
96	1-(2,4-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiology of Disease, 2010, 37, 177-185.	2.1	101
97	Antinociceptive activity of $\Delta^9$ -tetrahydrocannabinol non-ionic microemulsions. International Journal of Pharmaceutics, 2010, 393, 239-244.	2.6	7
98	A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. European Psychiatry, 2010, 25, 92-100.	0.1	16
99	Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. European Journal of Pharmacology, 2009, 620, 36-41.	1.7	6
100	Synthesis and <i>in vitro</i> Evaluation of Trifluoroethylamine Analogues of Enkephalins. ChemMedChem, 2009, 4, 1416-1420.	1.6	9
101	Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4715-4719.	1.0	8
102	Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opinion on Drug Delivery, 2009, 6, 319-331.	2.4	23
103	Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?. Annals of General Psychiatry, 2008, 7, .	1.2	0
104	Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration. European Journal of Pharmacology, 2008, 598, 16-20.	1.7	2
105	Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet. Computer Methods and Programs in Biomedicine, 2008, 90, 124-136.	2.6	4
106	Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. Clinical Drug Investigation, 2008, 28, 465-477.	1.1	28
107	Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice. Behavioural Brain Research, 2007, 183, 147-155.	1.2	11
108	Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. European Psychiatry, 2007, 22, 267-275.	0.1	65



#	ARTICLE	IF	CITATIONS
109	3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6-diazabicyclo[3.1.1]heptanes as novel potent dopamine uptake inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3748-3755.	1.4	10
110	Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. <i>Brain Research</i> , 2007, 1141, 15-24.	1.1	22
111	Eficacia de los antipsicóticos: relación con la ocupación óptima de los receptores D2. <i>European Psychiatry (Ed Española)</i> , 2007, 14, 325-334.	0.0	0
112	Tricyclic Pyrazoles. 4. Synthesis and Biological Evaluation of Analogues of the Robust and Selective CB2 Cannabinoid Ligand 1-(2,4-Dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7502-7512.	2.9	68
113	Evolutionary Psychopharmacology, Mental Disorders, and Ethical Behavior. , 2006, , 97-120.		2
114	Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3309-3320.	1.4	51
115	Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. <i>Chemistry and Physics of Lipids</i> , 2005, 135, 147-156.	1.5	30
116	Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. <i>European Journal of Pharmacology</i> , 2005, 525, 150-153.	1.7	7
117	Effect of $\delta^9$ -tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: An immunohistochemical study. <i>Brain Research</i> , 2005, 1048, 41-47.	1.1	34
118	Evaluation of Tamsulosin and Alfuzosin Activity in the Rat Vas Deferens: Relevance to Ejaculation Delays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 710-717.	1.3	22
119	Tricyclic Pyrazoles. 3. Synthesis, Biological Evaluation, and Molecular Modeling of Analogues of the Cannabinoid Antagonist 8-Chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7351-7362.	2.9	39
120	Five mutations in the GABAA $\alpha 6$ gene 5' flanking region are associated with a reduced basal and ethanol-induced $\alpha 6$ upregulation in mutated Sardinian alcohol non-preferring rats. <i>Molecular Brain Research</i> , 2005, 137, 252-257.	2.5	7
121	Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 997-1005.	1.1	69
122	Consensus on the Use of Substituted Benzamides in Psychiatric Patients. <i>Neuropsychobiology</i> , 2004, 50, 134-143.	0.9	42
123	Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. <i>European Journal of Pharmacology</i> , 2004, 483, 65-69.	1.7	12
124	The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. <i>European Journal of Pharmacology</i> , 2004, 504, 61-64.	1.7	51
125	The cerebellar GABAA $\alpha 6$ subunit is differentially modulated by chronic ethanol exposure in normal (R100R) and mutated (Q100Q) sNP rats. <i>Brain Research</i> , 2004, 998, 148-154.	1.1	7
126	Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats. <i>Psychopharmacology</i> , 2004, 172, 341-351.	1.5	33



#	ARTICLE	IF	CITATIONS
127	Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1921-1933.	1.4	36
128	Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. <i>Neuropharmacology</i> , 2004, 47, 128-135.	2.0	13
129	Haloperidol versus risperidone on rat "early onset"vacuous chewing. <i>Behavioural Brain Research</i> , 2004, 149, 9-16.	1.2	20
130	Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. <i>Psychopharmacology</i> , 2003, 167, 79-84.	1.5	55
131	Characterization of wild-type (R100R) and mutated (Q100Q) GABAA $\alpha 6$ subunit in Sardinian alcohol non-preferring rats (sNP). <i>Brain Research</i> , 2003, 967, 98-105.	1.1	11
132	Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. <i>European Journal of Pharmacology</i> , 2003, 459, 97-105.	1.7	72
133	Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. <i>Journal of Affective Disorders</i> , 2003, 73, 75-85.	2.0	89
134	In vitro evidence for the presence of [3 H]-haloperidol uptake in rat brain. <i>British Journal of Pharmacology</i> , 2003, 138, 188-192.	2.7	5
135	Haloperidol, but not clozapine, produces dramatic catalepsy in $\Delta^9$ -THC-treated rats: possible clinical implications. <i>British Journal of Pharmacology</i> , 2003, 140, 520-526.	2.7	30
136	Molecular characterization of new polymorphisms at the $\alpha 2$ , $\alpha 1$ , $\alpha 3$ GABAA receptor subunit genes associated to a rat nonpreferring ethanol phenotype. <i>Molecular Brain Research</i> , 2003, 110, 289-297.	2.5	11
137	Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1Cannabinoid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 363-370.	1.3	89
138	The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 247-253.	4.1	54
139	Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. <i>European Journal of Endocrinology</i> , 2002, 147, 255-261.	1.9	46
140	Effect of the amisulpride isomers on rat catalepsy. <i>European Journal of Pharmacology</i> , 2002, 444, 69-74.	1.7	13
141	Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. <i>European Journal of Pharmacology</i> , 2002, 447, 109-114.	1.7	9
142	Effect of the amisulpride isomers on rat prolactinemia. <i>European Journal of Pharmacology</i> , 2002, 448, 263-266.	1.7	4
143	Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 924, 242-251.	1.1	23
144	Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 948, 192-202.	1.1	16

#	ARTICLE	IF	CITATIONS
145	Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset"™ vacuum chewing. <i>European Journal of Neuroscience</i> , 2002, 15, 1187-1196.	1.2	42
146	Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis. <i>Toxicology Letters</i> , 2001, 121, 199-206.	0.4	32
147	The R100Q mutation of the GABAA $\alpha$ 6 receptor subunit may contribute to voluntary aversion to ethanol in the sNP rat line. <i>Molecular Brain Research</i> , 2001, 87, 263-270.	2.5	37
148	The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. <i>European Journal of Neuroscience</i> , 2001, 13, 409-412.	1.2	101
149	Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. <i>Molecular Psychiatry</i> , 2001, 6, 657-664.	4.1	174
150	( $\alpha$ )S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors. <i>European Journal of Pharmacology</i> , 2001, 432, 143-147.	1.7	20
151	The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. <i>European Journal of Neuroscience</i> , 2000, 12, 1123-1127.	1.2	88
152	The role of stress in the pathophysiology of the dopaminergic system. <i>Molecular Psychiatry</i> , 2000, 5, 14-21.	4.1	270
153	Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?. <i>Molecular Psychiatry</i> , 2000, 5, 467-475.	4.1	48
154	The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. <i>Molecular Psychiatry</i> , 2000, 5, 673-677.	4.1	20
155	$\Delta^9$ -Tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. <i>European Journal of Neuroscience</i> , 1998, 10, 1743-1751.	1.2	35
156	Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marijuana. <i>Molecular Brain Research</i> , 1998, 58, 240-245.	2.5	89
157	Rat tyrosine hydroxylase gene polymorphisms. <i>Molecular Brain Research</i> , 1997, 45, 345-348.	2.5	2
158	Fluoxetine-induced conditioned place preference: A preliminary study. , 1997, 25, 309-311.		12
159	Correlation between increased AP-1/NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells. <i>Molecular Brain Research</i> , 1996, 35, 1-10.	2.5	32
160	Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 277-281.	0.1	5
161	Chronic imipramine, l-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. <i>Neuroscience Letters</i> , 1995, 192, 121-123.	1.0	21
162	Sleep deprivation in the rat: an animal model of mania. <i>European Neuropsychopharmacology</i> , 1995, 5, 89-93.	0.3	156

#	ARTICLE	IF	CITATIONS
163	Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. <i>European Journal of Pharmacology</i> , 1994, 262, 107-111.	1.7	57
164	ACTH-induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in adrenals of hypophysectomized rats is not cause-effect related to its immediate steroidogenic action. <i>Life Sciences</i> , 1993, 53, 1137-1147.	2.0	15
165	Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3948-3952.	3.3	237
166	Cloning and tissue-specific functional characterization of the promoter of the rat diazepam binding inhibitor, a peptide with multiple biological actions.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8439-8443.	3.3	28
167	The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. <i>Brain Research Bulletin</i> , 1991, 26, 445-447.	1.4	75
168	Flunarizine attenuates cocaine-induced inhibition of A dopaminergic neurons. <i>Pharmacological Research</i> , 1991, 24, 197-203.	3.1	8
169	Inhibition of [3H]dopamine uptake by flunarizine. <i>European Journal of Pharmacology</i> , 1991, 203, 67-69.	1.7	13
170	Conditioned place preference induced by ethanol in a rat line selected for ethanol preference. <i>Pharmacological Research</i> , 1990, 22, 48.	3.1	12
171	The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). <i>Neuroscience Letters</i> , 1990, 117, 129-133.	1.0	73
172	Calcium receptor antagonists modify cocaine effects in the central nervous system differently. <i>European Journal of Pharmacology</i> , 1990, 190, 217-221.	1.7	92
173	Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats. <i>European Journal of Pharmacology</i> , 1990, 190, 223-227.	1.7	17
174	Stress increases noradrenaline release in the rat frontal cortex: Prevention by diazepam. <i>European Journal of Pharmacology</i> , 1990, 176, 229-231.	1.7	69
175	Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. <i>European Journal of Pharmacology</i> , 1990, 176, 245-246.	1.7	37
176	Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?. <i>European Journal of Pharmacology</i> , 1990, 180, 85-90.	1.7	37
177	Differential postmortem release of noradrenaline and dopamine from rat brain. <i>Psychopharmacology</i> , 1989, 98, 562-563.	1.5	8
178	Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. <i>European Journal of Pharmacology</i> , 1989, 163, 393-395.	1.7	36
179	Are D1 dopamine receptor agonists potential antidepressants?. <i>Pharmacological Research Communications</i> , 1988, 20, 1121-1122.	0.2	10
180	Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1